RFK Jr. Grants Enforcement Discretion for Six Unproven Peptides
The FDA’s position on six unproven peptides has been overridden by Health Secretary Robert F. Kennedy Jr., who has directed the agency to apply an enforcement discretion policy to them. The move grants the peptides continued access to the market despite the agency’s concerns.
These peptides have gained popularity among MAHA, a movement associated with the administration’s public-health agenda. Their use is not supported by proven effectiveness, according to the report.
The policy shift represents a direct departure from the FDA’s usual enforcement approach and highlights the administration’s willingness to prioritize access to unproven treatments over the agency’s assessment of their evidentiary basis.